Effects of Semaglutide on Heart and Liver Health in Diabetes
The Effect of Semaglutide on Endothelial Function, Arterial Stiffness and Liver Indices in Patients Witn Type 2 Diabetes Mellitus and NAFLD
This study is testing if the diabetes medication semaglutide can improve heart and liver health in people with type 2 diabetes and fatty liver disease compared to another treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Attikon Hospital Academic / other |
| Locations | 1 site (Athens) |
| Trial ID | NCT06301191 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of semaglutide on cardiovascular markers and liver function in patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Fifty participants will be enrolled, with half receiving semaglutide and the other half treated with Dipeptidyl Peptidase 4 (D-PP4) inhibitors. Evaluations will occur at baseline, four months, and twelve months, focusing on various vascular and liver function metrics. The study aims to clarify the cardiovascular benefits of semaglutide beyond its established effects.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with type 2 diabetes and non-alcoholic fatty liver disease.
Not a fit: Patients with malignancies, chronic inflammatory diseases, chronic kidney disease, peripheral vascular disease, retinopathy, or those previously treated with GLP-1 agonists may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into improving cardiovascular and liver health for patients with type 2 diabetes and NAFLD.
How similar studies have performed: While the cardiovascular benefits of semaglutide are established, this specific investigation into its effects on liver function and vascular markers is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diabetes Mellitus type 2 * NAFLD Exclusion Criteria: * malignancies * chronic inflammatory disease * chronic kidney disease (estimated glomerular filtration rate \<60 ml/min/m2 for a period of at least 90 days) * peripheral vascular disease * retinopathy * previous therapy with a Glucagon-like peptide-1 agonist. * None of the female patients was on hormone replacement treatment.
Where this trial is running
Athens
- Attikon University General Hospital — Athens, Greece (Recruiting)
Study contacts
- Study coordinator: VAIA LAMBADIARI, Professor
- Email: vlambad@otenet.gr
- Phone: 2105831148
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.